Hints and tips:
...Even the architect of NPS thinks few companies use it very well....
...Ben Loomes, Managing Partner and head of infrastructure at InfraRed, which is advising the HICL and NPS funds, said: We are very pleased to be investing in HS1, a strategically important and core UK infrastructure...
...Strong growth came from Shire’s newer rare disease drugs, such as those acquired from NPS Pharma last year for $5.2bn, but also from its older Vyvanse treatment for attention deficit hyperactivity disorder...
...Growth came from newer rare disease drugs, such as those acquired from NPS Pharma last year for $5.2bn, but also from its older Vyvanse treatment for attention deficit hyperactivity disorder, which was up...
...In addition to Baxalta, Shire bought two other US biotech companies, NPS and Dyax — each for more than $5bn — in the past year....
...From there, he moved to a series of smaller companies: Bristol-Myers, Vertex, NPS Pharma and Onyx. “Pretty soon, I’ll be washing glassware.”...
...Two deals with NPS Pharma and Dyax followed, but the pursuit of Baxalta was by far the most ambitious....
...“The head of the NPS is chosen by the government, so every time the government changes, it could influence private companies through the NPS.”...
...“I expect the NPS to make the same decision on Samsung....
...To that end, it recently bought NPS, a US-based rare disease specialist, for $5.2bn and is in the throes of a $30bn hostile takeover attempt of Baxalta, another US group, which focuses on rare blood disorders...
...drugs than NPS would have been on its own, or both....
...NPS also has an approved product already on sale in the US for a gastrointestinal disorder called short bowel syndrome....
...Analysts have said that, if approved, it would significantly bolster the value of NPS....
...Elliott on Monday wrote a letter to the NPS but the NPS said it had not yet decided how to vote. Additional reporting by Kang Buseong...
...A physician survey suggested that the two drugs could be worth $9bn on present value, against Shire’s NPS purchase price in January of $5.2bn, UBS said....
...Flemming Ornskov, chief executive, is mainly focused on expanding into treatments for rare diseases such as the Natpara drug acquired from NPS....
...Shire has already committed the break fee to help finance its $5.2bn acquisition of US-based NPS Pharmaceuticals, agreed last month, as it resumes its expansion as a standalone company focused on speciality...
...Valeant announced a $14.5bn deal to acquire Salix over the weekend; Pfizer announced a $17bn deal to buy Hospira earlier this month; and UK-listed Shire acquired NPS in a $5.2bn deal in January....
...The NPS effectively blocked a tie-up last year between Samsung Heavy Industries and Samsung Engineering by taking up an option to sell its stock back to the companies, which scrapped the deal saying the...
...Roche, Johnson & Johnson and Biogen Idec were among drugmakers to announce tie-ups on Monday, a day after Shire agreed to buy NPS Pharmaceuticals for $5.2bn....
...The NPS has taken stands against chaebol management: it opposed the re-election of two Hyundai Motor Group company directors over the Seoul land purchase and last month voted against the merger of two SK...
...Shire will pay £3.2bn for US biotech business NPS Pharmaceuticals. That equates to $46 a share — a 51 per cent premium to the NPS share price on 16 December 2014....
...Since the start of the year, Valeant has acquired gastrointestinal drugmaker Salix for $14.5bn, Pfizer bought medical device maker Hospira for $17bn and Shire picked up NPS Pharma for $5.2bn....
...So far this year, Valeant has acquired gastrointestinal drugmaker Salix for $14.5bn, Pfizer bought Hospira for $17bn and Shire picked up NPS Pharma for $5.2bn....
...“Everything now depends on what the NPS decides,” said Mr Lee at the Centre for Good Corporate Governance. “But there’s no way of predicting what they’ll do.”...
International Edition